Our Pricing

The Science Behind Mounjaro When Prescribed

Understanding how does Mounjaro work scientifically UK helps patients make informed decisions about their weight management journey. Mounjaro (tirzepatide) represents a breakthrough in obesity treatment as the first dual GIP/GLP-1 receptor agonist licensed by the MHRA, working through two complementary hormonal pathways to regulate appetite, blood sugar, and body weight. At Cured Pharmacy, our UK-registered clinical team provides evidence-based consultations to determine if Mounjaro is appropriate for your individual circumstances.

How Does Mounjaro Work Scientifically: The Dual Receptor Mechanism

Mounjaro contains tirzepatide, a synthetic peptide that simultaneously activates two incretin hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [1]. This dual-agonist approach distinguishes it from single-pathway treatments like semaglutide (Wegovy) or liraglutide (Saxenda), which target only GLP-1 receptors.

When administered as a once-weekly subcutaneous injection, tirzepatide binds to GIP receptors primarily in pancreatic beta cells and adipose tissue, whilst GLP-1 receptor activation occurs throughout the body including the brain's appetite centres, pancreas, and gastrointestinal tract [1]. This coordinated action produces complementary metabolic effects that enhance overall efficacy.

The GLP-1 component slows gastric emptying, increases satiety signalling to the hypothalamus, and stimulates glucose-dependent insulin secretion whilst suppressing inappropriate glucagon release [2]. Simultaneously, GIP receptor activation improves insulin sensitivity, enhances energy expenditure in adipose tissue, and may reduce food intake through central nervous system pathways [1]. Clinical evidence suggests this dual mechanism produces superior weight reduction compared to GLP-1 monotherapy.

Clinical Trial Evidence: SURPASS and SURMOUNT Studies

The scientific foundation for Mounjaro's efficacy comes from the comprehensive SURPASS clinical trial programme, which enrolled over 10,000 participants across multiple studies [1]. In the pivotal SURMOUNT-1 trial examining tirzepatide specifically for weight management in adults without diabetes, participants achieved average body weight reductions of 15.0%, 19.5%, and 20.9% with the 5mg, 10mg, and 15mg doses respectively over 72 weeks [3].

These results significantly exceeded those observed with placebo (3.1% weight reduction) and represented the highest average weight loss achieved in any obesity medication trial to date [3]. Importantly, 89% of participants on the 15mg dose achieved at least 5% body weight reduction—the threshold considered clinically meaningful—whilst 57% achieved the more ambitious target of 20% or greater reduction [3].

The SURPASS-3 trial, which directly compared tirzepatide against semaglutide 1mg in adults with type 2 diabetes, demonstrated superior glycaemic control and weight reduction with tirzepatide across all dose levels [4]. Participants on tirzepatide 15mg achieved an average 13.9kg weight reduction compared to 7.0kg with semaglutide, providing head-to-head evidence of the dual receptor mechanism's enhanced efficacy [4].

Long-Term Sustainability and Maintenance

Extension studies from the SURMOUNT programme demonstrate that weight reduction achieved with tirzepatide can be sustained with continued treatment beyond the initial 72-week period [3]. However, as with all weight management medications, discontinuation typically results in gradual weight regain, emphasising the importance of viewing tirzepatide as part of a long-term management strategy rather than a short-term intervention.

UK prescribers typically recommend ongoing lifestyle modifications including dietary changes and increased physical activity alongside pharmacotherapy to optimise outcomes and support weight maintenance. Your clinical assessment at Cured Pharmacy will include discussion of these complementary approaches to ensure realistic expectations and sustainable results.

Mounjaro Dosing Schedule and Titration Protocol

Mounjaro treatment follows a structured dose-escalation protocol designed to minimise gastrointestinal side effects whilst achieving therapeutic efficacy. All patients begin with the 2.5mg starter dose administered once weekly for four weeks, regardless of their target maintenance dose [5].

After the initial month, the dose increases to 5mg weekly for at least four weeks. Based on individual response and tolerability, your UK prescriber may recommend further increases to 7.5mg, 10mg, 12.5mg, or the maximum 15mg dose, with each increment maintained for a minimum of four weeks [5]. This gradual titration allows your body to adapt to the medication's effects on gastric emptying and appetite regulation.

The KwikPen delivery device used for Mounjaro contains four pre-filled doses at a single strength, making weekly administration straightforward. Injections are given subcutaneously into the abdomen, thigh, or upper arm, with injection sites rotated to prevent lipodystrophy. Detailed administration training is provided with your first prescription, and our pharmacy team remains available for ongoing support throughout your treatment journey.

How Does Mounjaro Work Scientifically Compared to Other Weight Loss Treatments

Whilst Mounjaro, Wegovy, and Saxenda all belong to the incretin mimetic class, their differing mechanisms produce distinct clinical profiles. Wegovy (semaglutide) activates only GLP-1 receptors and is administered weekly, achieving average weight reductions of approximately 15% over 68 weeks in the STEP trials [6]. Saxenda (liraglutide), also a GLP-1-only agonist, requires daily injections and produces more modest average reductions of 8% over 56 weeks [7].

Mounjaro's dual GIP/GLP-1 mechanism appears to produce superior weight reduction compared to GLP-1 monotherapy, though individual responses vary considerably based on baseline characteristics, adherence, and lifestyle factors [1][3]. The choice between these medications depends on multiple factors including your medical history, treatment goals, injection frequency preference, and cost considerations.

Non-incretin weight management options like Orlistat work through an entirely different mechanism—blocking fat absorption in the intestine rather than modulating appetite hormones. Orlistat may be appropriate for patients who prefer oral medication or have contraindications to incretin therapy, though average weight reduction is typically lower at approximately 3-5% [8]. Your UK prescriber will discuss these alternatives during your clinical assessment to identify the most suitable option for your circumstances.

Eligibility Criteria for Mounjaro Prescription

In the UK, Mounjaro is licensed for weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea [5]. Your prescriber will calculate your BMI and assess relevant health conditions during your online consultation.

Certain medical conditions preclude Mounjaro use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy requiring active treatment [5]. Pregnancy and breastfeeding are also contraindications. A thorough medical history review ensures safe prescribing aligned with MHRA licensing and clinical guidelines.

Common Side Effects and Management Strategies

The most frequently reported side effects with Mounjaro are gastrointestinal in nature, reflecting the medication's effects on gastric emptying and gut motility. In clinical trials, nausea occurred in 20-30% of participants, diarrhoea in 15-20%, vomiting in 8-12%, and constipation in 6-10%, with incidence varying by dose level [3][5].

These effects are typically mild to moderate in severity, occur most commonly during dose escalation periods, and tend to diminish over time as tolerance develops. Eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and taking the injection on the same day each week can help minimise gastrointestinal symptoms.

Less common but more serious potential adverse effects include acute pancreatitis (occurring in <1% of trial participants), gallbladder disease, hypoglycaemia when used with other glucose-lowering medications, and allergic reactions [5]. Any severe abdominal pain, persistent vomiting, signs of pancreatitis, or allergic symptoms warrant immediate medical attention and treatment discontinuation pending clinical review.

When to Contact Your Prescriber

Whilst most patients tolerate Mounjaro well with appropriate dose titration, certain symptoms require prompt clinical review. Contact your prescriber if you experience severe or persistent nausea and vomiting preventing adequate fluid intake, signs of dehydration, sudden severe abdominal pain radiating to the back, visual changes, or symptoms of thyroid nodules such as a lump in the neck or persistent hoarseness.

Our clinical team at Cured Pharmacy remains available throughout your treatment for medication reviews, side effect management, and dose adjustments. Regular monitoring ensures your treatment remains safe, effective, and aligned with your weight management goals.

Starting Mounjaro Treatment at Cured Pharmacy

Beginning treatment with Mounjaro requires a clinical assessment by a UK-registered prescriber to confirm eligibility, review your medical history, and discuss realistic expectations. At Cured Pharmacy, this consultation is completed online in under three minutes through our secure platform, with transparent upfront pricing showing you'll pay from £135.00 before you begin the assessment.

If Mounjaro is deemed clinically appropriate following your consultation, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) under the supervision of our Superintendent Pharmacist Tarun Kumar (GPhC 2233073). All medications are genuine UK-licensed products supplied in discreet packaging with next-day delivery options available.

Your initial supply will include the 2.5mg starter dose with comprehensive administration instructions. Follow-up consultations at four-week intervals allow dose titration based on your response and tolerability, ensuring you progress safely through the escalation protocol. Our pharmacy team provides ongoing support for injection technique questions, side effect management, and prescription renewals throughout your treatment journey.

Scientific References

1. Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
2. Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(Suppl 1), 5–21. https://doi.org/10.1111/dom.13129
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Ludvik, B., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
5. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). https://www.medicines.org.uk/emc/product/14881
6. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
7. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
8. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.